| Developing guidelines for biotechnology drug use: experience with antithrombin III. | |
| | |
MedLine Citation:
|
PMID: 10151737 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P & T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P & T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III. |
| | |
Authors:
|
D R Romac; P Poole; J T Owings; K Mahackian; G Foulke; R S Tharratt; T E Albertson |
Related Documents
:
|
8937997 - Management of the febrile infant. 11777607 - International harmonisation of anthelmintic efficacy guidelines (part 2). 2023797 - How to succeed in science. 9927247 - Including practice data to improve evidence-based guidelines. example of guidelines on ... 16741677 - Abamectin in the aquatic environment. 8937997 - Management of the febrile infant. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Formulary (Cleveland, Ohio) Volume: 30 ISSN: 1082-801X ISO Abbreviation: Formulary Publication Date: 1995 Sep |
Date Detail:
|
Created Date: 1995-12-21 Completed Date: 1995-12-21 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9513311 Medline TA: Formulary Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 520-3, 525-7, 531 Citation Subset: H |
Affiliation:
|
UC Davis Medical Center, Sacramento, CA 95817, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antithrombin III
/
therapeutic use* Antithrombin III Deficiency Biotechnology / standards* California Clinical Trials as Topic Deficiency Diseases / drug therapy Hospitals, University / organization & administration, standards* Humans Pharmacists Pharmacy and Therapeutics Committee* Physicians Practice Guidelines as Topic* Program Development |
| Chemical | |
Reg. No./Substance:
|
9000-94-6/Antithrombin III |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Results of our national survey. Current formulary decision-making strategies and new factors influen...
Next Document: Pharmacoeconomic issues in the treatment of depression.